Related Experiment Video
Updated: May 20, 2025
Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging
Published on: April 6, 2014
Microglial NOX2 as a therapeutic target in traumatic brain injury: Mechanisms, consequences, and potential for
Nargis Bano1, Sameera Khan1, Shakir Ahamad2
1Department of Zoology, Aligarh Muslim University, Aligarh 202002, India.
Abstract:
Traumatic brain injury (TBI) is a leading cause of long-term disability worldwide, with secondary injury mechanisms, including neuroinflammation and oxidative stress, driving much of its chronic pathology. While NADPH oxidase 2 (NOX2)-mediated reactive oxygen species (ROS) production is a recognized factor in TBI, the specific role of microglial NOX2 in perpetuating oxidative and inflammatory damage remains underexplored. Addressing this gap is critical, as current therapeutic approaches primarily target acute symptoms and fail to interrupt the persistent neuroinflammation that contributes to progressive neurodegeneration. Besides NOX, other ROS-generating enzymes, such as CYP1B1, COX2, and XO, also play crucial roles in triggering oxidative stress and neuroinflammatory conditions in TBI. However, this review highlights the pathophysiological role of microglial NOX2 in TBI, focusing on its activation following injury and its impact on ROS generation, neuroinflammatory signaling, and neuronal loss. These insights reveal NOX2 as a critical driver of secondary injury, linked to worsened outcomes, particularly in aged individuals where NOX2 activation is more pronounced. In addition, this review evaluates emerging therapeutic approaches targeting NOX2, such as GSK2795039 and other selective NOX2 inhibitors, which show potential in reducing ROS levels, limiting neuroinflammation, and preserving neurological functions. By highlighting the specific role of NOX2 in microglial ROS production and secondary neurodegeneration, this study advocates for NOX2 inhibition as a promising strategy to improve TBI outcomes by addressing the unmet need for therapies targeting long-term inflammation and neuroprotection. Our review highlights the potential of NOX2-targeted interventions to disrupt the cycle of oxidative stress and inflammation, ultimately offering a pathway to mitigate the chronic impact of TBI.
Insights
Microglial NADPH oxidase 2 (NOX2) drives secondary injury in traumatic brain injury (TBI) through oxidative stress and neuroinflammation. Targeting NOX2 offers a promising therapeutic strategy for TBI neuroprotection and mitigating chronic disability.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Traumatic brain injury (TBI) is a major cause of long-term disability, with secondary injury mechanisms like neuroinflammation and oxidative stress contributing to chronic pathology.
- Microglial NADPH oxidase 2 (NOX2) is implicated in TBI, but its specific role in sustained oxidative and inflammatory damage requires further exploration.
- Current TBI therapies often fail to address persistent neuroinflammation, highlighting the need for novel neuroprotective strategies.
Purpose of the Study:
- To elucidate the pathophysiological role of microglial NOX2 in TBI, focusing on its activation, impact on reactive oxygen species (ROS) generation, and contribution to neuroinflammation and neuronal loss.
- To evaluate emerging therapeutic strategies targeting NOX2 for TBI treatment.
Main Methods:
- Review of existing literature on NOX2 function in TBI.
- Analysis of NOX2 activation pathways and downstream effects in microglial cells.
- Evaluation of preclinical data for NOX2 inhibitors in TBI models.
Main Results:
- Microglial NOX2 activation post-TBI significantly contributes to ROS production, neuroinflammatory signaling, and neuronal damage.
- NOX2 plays a critical role in secondary injury progression, with exacerbated effects in aged individuals.
- Selective NOX2 inhibitors, such as GSK2795039, demonstrate potential in reducing ROS, limiting neuroinflammation, and preserving neurological function.
Conclusions:
- Microglial NOX2 is a key mediator of secondary injury and chronic neurodegeneration in TBI.
- Targeting NOX2 presents a promising therapeutic avenue to interrupt the cycle of oxidative stress and inflammation in TBI.
- NOX2 inhibition offers a potential strategy for long-term neuroprotection and improved outcomes in TBI patients.
